Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study.
Giacomo CaldarolaAndrea ChiricozziMatteo MegnaP DapavoA GiuntaM BurlandoP MalagoliV DiniMarco MarianiGabriella FabbrociniP QuaglinoLuca BianchiA ParodiKetty PerisC De SimonePublished in: Expert opinion on biological therapy (2023)
We found that ixekizumab is a biological agent characterized by long-term effectiveness, not influenced by several clinical factors and associated with a good safety profile.